Περίληψη:
To evaluate the presence in serum and the clinical relevance of several
antinuclear autoantibodies, we investigated 31 patients with initially
diagnosed gastric cancer and 40 age-matched healthy controls.
Autoantibodies against ssDNA, dsDNA, cardiolipin, actin, myosin,
tropomyosin, GM(1), GD(1b) and GT(3) gangliosides, were detected with an
enzyme-linked immunoassay (ELISA). Anti-ssDNA, anti-actin, anti-GM(1)
and anti-GD(1b) antibodies were detected in the serum of 11 (p = 0.001),
8 (p = 0.02), 11 (p = 0.001), and 9 (p = 0.008) patients with gastric
cancer, respectively. There was no significant difference between
patients with cancer and the control group, as far as the other
autoantibodies were concerned. Most of the patients (90%) had
autoantibodies against at least one of the antigens examined. Patients
with anti-ssDNA, anti-actin, anti-GM(1) and anti-GD(1b) antibodies were
less likely to survive than the patients being negative to the above
autoantibodies: the figures are 1 of 11 (9%) compared with 4 of 20
(20%); 1 of 8 (13%) compared with 5 of 23 (22%); 1 of 11 (9%)
compared with 4 of 20 (20%); and 1 of 9 (11%) compared with 4 of 22
(18%), respectively. Our findings suggest that 4 of the 9
autoantibodies that we assayed are significantly more likely to be found
in serum of patients with gastric cancer, indicating that the immune
system has a role in the process of the malignant disease. If our
results are confirmed by forthcoming studies, some of the immunological
variables that we examined could be used as markers of prognostic value
in patients with gastric cancer.
Συγγραφείς:
Konstandoulakis, MM
Syrigos, KN
Leandros, M
Charalabopoulos,
A
Manouras, A
Golematis, BC
